Patients Clinical Trial
Official title:
The Effects of Preoperative Scopolamine Patch Application on the Postoperative Nausea and Vomiting in Microvascular Decompression Surgery
A Single-center, randomized, prospective, experimental, double-blind comparison study for effects of preoperative scopolamine patch application on the postoperative nausea and vomiting in microvascular decompression surgery
1. Study design and plan
1-1) Sixty envelopes will be prepared: Thirty envelopes of scopolamine patch for
experimental group and 30 of placebo patch for control group. Each envelope will be
tagged for QR code, randomly mixed and numbered from 1 to 60. QR code will be
identified after discontinuation of study, so both researchers and subjects would not
know in which group the envelope is belonged to.
1-2) Patch will be applied under the ear of the opposite side of operation, at 9 p.m.
of the day before the operation day.
1-3) Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at
a recovery room and the ward. After that, nausea will be continuously assessed every 4
hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will
also be counted. Basic clinical characteristics and the number of antiemetic
administration will be identified through medical records.
2. Efficacy assessment
2-1) Degree of nausea: Visual Analogue Scale (VAS) Subjects will describe their subject
degree of nausea by VAS score, just immediate after arrival at a recovery room or the
ward and 4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery. Respondents specify their
degree of nausea by indicating a point along a continuous 10cm line between two
end-points; left one is for "No nausea" and the right one for "Very severe nausea".
Scoring is based on the length from left point and higher score means more severe
degree of nausea.
2-2) Number of vomiting Number of vomiting is counted from immediate after arrival at
recovery room or the ward, 4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after operation and
will be recorded. If there is no vomiting, it will be recorded as "0".
2-3) Number of antiemetic administration It will be recorded from immediate after
arrival at recovery room or the ward, 4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after
operation. The kind of antiemetic used and the dosage or number of administration can
be identified through medical records.
2-4) Type of antiemetic and time of administration 2-4-1) PRN) Meckool 10mg/2ml 1amp
IVs When VAS is more than 5 or when subjects want at minimum interval of 6hour and
maximum of three times. If there is no improvement, it will be noticed.
2-4-2) PRC) Nasea 0.3mg 1amp IVs
3. Statistical plans
3-1) General characteristics and clinical characteristics will be analyzed by
frequency, percentage, mean value and standard deviation.
3-2) Homogeneity of variances between experimental group and control group will be
analyzed by Chi-square test, t-test and Fisher's exact test 3-3) Degree of nausea
between experimental group and control group at recovery room or the ward, 4hr, 8hr,
12hr, 16hr, 20hr, and 24hr after operation will be analyzed by Student's t-test.
3-4) Number of vomiting and antiemetic administration between experimental group and
control group will be analyzed by Fisher's exact test.
3-5) Hospitalization period between experimental group and control group will be
analyzed by Student's t-test.
4. Experimental group of scopolamine patch application will be expected to have less
severity of nausea and fewer numbers of vomiting or antiemetic usages. Ultimately, this
may relate to hospitalization period and it will be decreased.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03943121 -
The Effects of Steroid-eluting Stent Implant for the Treatment of Eosinophilic Chronic Rhinosinusitis With Nasal Polyps
|
N/A | |
Not yet recruiting |
NCT06040151 -
Evaluating Mobile-based Medication Reconciliation by Patients at Home
|
||
Completed |
NCT04151004 -
Functional Muscle Characteristics and Cardio-respiratory Interaction in Patients With Fontan Palliation
|
N/A | |
Completed |
NCT01240967 -
To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function
|
Phase 1 | |
Recruiting |
NCT06373614 -
The Effect of Foot Massage and Bed Bath on Individuals With Cancer
|
N/A | |
Recruiting |
NCT06396442 -
Patient Worries Previous to Dental Treatment
|
||
Recruiting |
NCT05088161 -
Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques
|
||
Completed |
NCT03153579 -
LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders
|
Phase 2 | |
Completed |
NCT03790839 -
Drug Interaction Study Between Dorzagliatin and Sitagliptin
|
Phase 1 | |
Completed |
NCT02882672 -
Changes in Adiponectin and Cardiovascular Disease Risk Factors in Overweight Patients
|
Phase 1 | |
Withdrawn |
NCT03837418 -
DESIGNING A PROGRAMMING LANGUAGE FOR PATIENT-ORIENTED PRESCRIPTIONS (POP-PL)
|
||
Completed |
NCT03282630 -
The Effects of Sphenopalatine Ganglion Acupuncture in Patients With Seasonal Allergic Rhinitis
|
N/A | |
Recruiting |
NCT00001711 -
Magnetic Resonance Imaging (MRI) Ofl Volunteers
|
||
Completed |
NCT02820168 -
Designing a Programming Language for Patient-Oriented Prescriptions
|
||
Completed |
NCT01706744 -
Effect of Discharge Via an Intermediate Care Unit
|
N/A | |
Completed |
NCT04584554 -
Enhancing the Transition From Hospital to Home for Patients With Traumatic Brain Injury and Families
|
N/A | |
Completed |
NCT05660707 -
Patients Who Underwent Surgical Procedures State of Readiness for Discharge
|
||
Completed |
NCT04632277 -
Is Mg do Improve the Glycemic Control in Patients Drink a Desalinate Water
|
N/A | |
Completed |
NCT05576701 -
Laughter Therapy Application in Hemodialysis Patients
|
N/A | |
Completed |
NCT03790787 -
Drug Interaction Study Between Dorzagliatin and Empagliflozin
|
Phase 1 |